<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Urologiia</journal-id><journal-title-group><journal-title xml:lang="en">Urologiia</journal-title><trans-title-group xml:lang="ru"><trans-title>Урология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1728-2985</issn><issn publication-format="electronic">2414-9020</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">680347</article-id><article-id pub-id-type="doi">10.18565/urology.2024.6.95-100</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Results of kidney transplantation in patients with end-stage renal disease caused by glomerulonephritis</article-title><trans-title-group xml:lang="ru"><trans-title>Результаты трансплантации почек у пациентов с терминальной стадией почечной недостаточности, вызванной гломерулонефритом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5891-6327</contrib-id><name-alternatives><name xml:lang="en"><surname>Sholan</surname><given-names>R.</given-names></name><name xml:lang="ru"><surname>Шолан</surname><given-names>Рашад</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><bio xml:lang="en"><p>Ph.D., MD, Head of The Scientific Experimental Center</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, начальник центра</p></bio><email>reshadsholan@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aliyev</surname><given-names>R.</given-names></name><name xml:lang="ru"><surname>Алиев</surname><given-names>Р.</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><bio xml:lang="en"><p>Ph.D., MD, associate professor, Major General of the Medical Service, Head of State Security Services General Department of Military Medicine</p></bio><bio xml:lang="ru"><p>доцент, доктор философии по медицине, генерал-майор медицинской службы, начальник Главного военно-медицинского управления</p></bio><email>mqos@yandex.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7740-0972</contrib-id><name-alternatives><name xml:lang="en"><surname>Hashimova</surname><given-names>U.</given-names></name><name xml:lang="ru"><surname>Гашимова</surname><given-names>У.</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><bio xml:lang="en"><p>Ph.D. in Biology, professor, Director of the Institute</p></bio><bio xml:lang="ru"><p>докт.биол.н., профессор, директор Института</p></bio><email>ulduz.hashimova@science.az</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-2917-3039</contrib-id><name-alternatives><name xml:lang="en"><surname>Almazkhanli</surname><given-names>A.</given-names></name><name xml:lang="ru"><surname>Алмазханлы</surname><given-names>А.</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><bio xml:lang="en"><p>State Security Service, Military Hospital, Department of Kidney Diseases and Organ Transplantation</p></bio><bio xml:lang="ru"><p>отделение «Почечные болезни и трансплантации органов»</p></bio><email>almazxanlianar@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-1790-9102</contrib-id><name-alternatives><name xml:lang="en"><surname>Bakhsheliyeva</surname><given-names>N.</given-names></name><name xml:lang="ru"><surname>Бахшелиева</surname><given-names>Н.</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><bio xml:lang="en"><p>State Security Service, Military Hospital, Department of Kidney Diseases and Organ Transplantation</p></bio><bio xml:lang="ru"><p>отделение «Почечные болезни и трансплантации органов»</p></bio><email>nergiz.baxseliyeva1990@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-0474-8106</contrib-id><name-alternatives><name xml:lang="en"><surname>Yusifova</surname><given-names>A.</given-names></name><name xml:lang="ru"><surname>Юсифова</surname><given-names>А.</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><bio xml:lang="en"><p>State Security Service, Military Hospital, Department of Kidney Diseases and Organ Transplantation</p></bio><bio xml:lang="ru"><p>отделение «Почечные болезни и трансплантации органов»</p></bio><email>aydanyusifova1990@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-4986-3244</contrib-id><name-alternatives><name xml:lang="en"><surname>Sefihanova</surname><given-names>K.</given-names></name><name xml:lang="ru"><surname>Сафиханова</surname><given-names>Х.</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><email>khatira.safikhanova.74@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3435-9981</contrib-id><name-alternatives><name xml:lang="en"><surname>Gaisina</surname><given-names>A.</given-names></name><name xml:lang="ru"><surname>Гаисина</surname><given-names>А.</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><email>aliyagaisina@hotmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-3347-3960</contrib-id><name-alternatives><name xml:lang="en"><surname>Mammadova</surname><given-names>N.</given-names></name><name xml:lang="ru"><surname>Мамедова</surname><given-names>Н.</given-names></name></name-alternatives><address><country country="AZ">Azerbaijan</country></address><email>narminka1@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Military Hospital, Scientific Experimental Center</institution></aff><aff><institution xml:lang="ru">Научно-экспериментальный центр Службы государственной безопасности</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">State Security Service, Military Hospital</institution></aff><aff><institution xml:lang="ru">Военный госпиталь Главного военно-медицинского управления Службы государственной безопасности</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">A. Karayev’s Institute of Physiology, Azerbaijan National Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт физиологии им. Абдулла Гараева Министерства науки и образования Азербайджанской Республики</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-12-10" publication-format="electronic"><day>10</day><month>12</month><year>2024</year></pub-date><issue>6</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>92</fpage><lpage>97</lpage><history><date date-type="received" iso-8601-date="2025-05-24"><day>24</day><month>05</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-05-24"><day>24</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО «Бионика Медиа»</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/1728-2985/article/view/680347">https://journals.eco-vector.com/1728-2985/article/view/680347</self-uri><abstract xml:lang="en"><p><bold>Aim</bold><bold>.</bold> To analyze own 3-year results of kidney transplantation after hemodialysis in patients with chronic glomerulonephritis.</p> <p><bold>Materials</bold><bold> </bold><bold>and</bold><bold> </bold><bold>methods</bold><bold>.</bold> Living-donor kidney transplantation was performed in 49 patients with end-stage kidney disease. All patients were first-time recipients. They received tacrolimus. After induction immunosuppression, 3-component supportive immunosuppressive therapy was used according to the following scheme: calcineurin inhibitors (tacrolimus), antiproliferative drug (mycophenolate mofetil; Cellcept) and glucocorticoids (prednisolone). In 16.3% of patients, the nephrotoxic effect of tacrolimus was seen and they were prescribed an mTOR inhibitor (everolimus). Body mass index (BMI), serum creatinine level before and after transplantation, glomerular filtration rate (GFR), panel-reactive antibodies, as well as donor-specific antibodies were determined. Panel-reactive antibodies were detected using Gen-Probe-Lifecodes and Luminex-200 screening kits (Luminex Corporation, Austin, Texas, USA). Detection of donor-specific antibodies in the recipient (DSA-test) was carried out according to the cross-match test. For statistical processing, the statistical package Statistica 16.0, Excel 2016 was used.</p> <p><bold>Results</bold><bold>.</bold> The average age of the recipients was 33.61±7.89 years. The duration of hemodialysis was 23.49±14.23 months, in 12.2% of cases transplantation was performed without prior hemodialysis. The mean fluorescence intensities of HLA classes I and II was 249.96±200.57 and 251.48±282.44, respectively. HLA compatibility was 41.16±16.68. Donor-specific antibodies were absent. The average age of donors was 49.39±7.97 years, and 71.4% of donors were first-degree relatives. After 1 day, the serum creatinine level decreased by 53.6% in comparison with the baseline value (<italic>p</italic><italic>=</italic>0.093). After 3 and 7 days, the difference with the initial creatinine level was 72.8% (<italic>p</italic><italic>=</italic>0.027) and 75.7% (<italic>p</italic><italic>=</italic>0.022). In 53.1% of cases, the HLA compatibility was 50.0%. The panel-reactive antibodies were negative in 2.0% of cases. There were no lethal outcomes. Acute cellular and humoral rejection developed in 1 (2.0%) patient. After transplantation, rejection was observed in 5 (10.2%) recipients.</p> <p><bold>Conclusion</bold><bold>.</bold> Analysis of our data indicates satisfactory results of kidney transplantation in the Republican Diagnostic and Treatment Center, which indicates the necessity of continuation of the program of transplantation with the analysis of HLA subclasses.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования.</bold> Анализ собственных результатов 3-летнего наблюдения трансплантации почек после гемодиализа у пациентов с хроническим гломерулонефритом.</p> <p><bold>Материалы и методы.</bold> Трансплантация почек от живого донора выполнена 49 пациентам с терминальной почечной недостаточностью. Все пациенты были реципиентами первого трансплантата. Все пациенты принимали такролимус. После индукционной иммуносупрессии применялась 3-компонентная поддерживающая иммуносупрессивная терапия по схеме: ингибиторы кальциневрина (такролимус), антипролиферативный препарат – микофенолат мофетил – (Cellcept) и глюкокортикоиды (преднизолон). У 16,3% пациентов наблюдалось нефротоксическое действие такролимуса, им был назначен ингибитор М-ТОР (еверолимус).</p> <p>В рамках обследования пациентов определялись: индекс массы тела (ИМТ), креатинин в сыворотке крови до и после трансплантации, скорость клубочковой фильтрации (СКФ), панель реактивных антител, донор-специфические антитела. Определение реактивных антител выполнено с помощью наборов для скрининга Gen-Probe-Lifecodes и Luminex-200 (Luminex Corporation, Остин, Техас, США). Выявление донор-специфических антител у реципиента – DSA-тест – проводилось по реакции cross-match. Для статистической обработки использован статистический пакет Statistica 16.0, Excel 2016.</p> <p><bold>Результаты.</bold> Средний возраст реципиентов составил 33,61±7,89 года. Длительность гемодиализа – 23,49±14,23 мес, в 12,2% случаев трансплантация проведена без предварительного гемодиализа. Средняя интенсивность флуоресценции HLA I и II класса составила 249,96±200,57 и 251,48±282,44 соответственно. Соответствие HLA составило 41,16±16,68. Донор-специфические антитела отсутствовали. Средний возраст доноров – 49,39±7,97 года, доноры с I степенью генетического родства составили 71,4%. После первых суток концентрация креатинина в сравнении с величиной на момент поступления снизилась на 53,6% (р=0,093). Спустя трое и семеро суток разница с исходным уровнем креатинина составила 72,8% (р=0,027) и 75,7% (р=0,022). В 53,1% случаев соответствие HLA составило 50,0%. Панель реактивных антител была негативна в 2,0% случаев. Смертельных случаев не было. Осложнение в виде острого клеточного и гуморального отторжения развилось у одного (2,0%) пациента. После трансплантации отторжение наблюдалось у пяти (10,2%) реципиентов.</p> <p><bold>Заключение.</bold> Анализ собственного клинического материала указывает на удовлетворительные результаты трансплантации почек в Республиканском лечебно-диагностическом центре, что свидетельствует о необходимости продолжения проведения трансплантации с анализом подклассов HLA.</p></trans-abstract><kwd-group xml:lang="en"><kwd>kidney transplantation</kwd><kwd>glomerulonephritis</kwd><kwd>end-stage renal disease</kwd><kwd>panel-reactive antibody</kwd><kwd>donor-specific antibodies</kwd><kwd>rejection</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>трансплантация почек</kwd><kwd>гломерулонефрит</kwd><kwd>терминальная стадия почечной недостаточности</kwd><kwd>панель реактивных антител</kwd><kwd>донор- специфические антитела</kwd><kwd>отторжение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, et al. OPTN/SRTR 2019 Annual Data Report: Kidney. Am J Transplant. 2021;21(2):21-137. DOI: 10.1111/ajt.16502.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Yagisawa T, Mieno M, Ichimaru N, Morita K, Nakamura M, Hotta K, et al. Trends of kidney transplantation in Japan in 2018: data from the kidney transplant registry. Ren Replace Ther. 2019; 5.3:1-14. DOI: 10.1186/s41100-019-0199-6</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lorent M, Foucher Y, Kerleau K, Brouard S, Baayen C, Lebouter S, et al. The EKiTE network (epidemiology in kidney transplantation – a European validated database): an initiative epidemiological and translational European collaborative research. BMC Nephrol. 2019;20:365. DOI: 10.1186/s12882-019-1522-8</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Pinchuk AV, Shmarina NV, Dmitriev IV, Vinogradov VE, Kazantsev AI. Analysis of recipient and graft survival after primary and second kidney transplantation. Russian Journal of Transplantology and Artificial Organs. 2021;23(2):21-29. DOI: 10.15825/1995-1191-2021-2-21-29. Russian (Пинчук АВ, Шмарина НВ, Дмитриев ИВ, Виноградов ВЕ, Казанцев АИ. Анализ выживаемости реципиентов и трансплантатов после первичной и повторной трансплантации почки. Вестник трансплантологии и искусственных органов. 2021;23(2):21-29. DOI: 10.15825/1995-1191-2021-2-21-29).</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; published online Feb 13. DOI: 10.1016/S0140-6736(20)30045-3.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kennard AL, Jiang SH, Walters GD. Increased glomerulonephritis recurrence after living related donation. BMC Nephrol. 2017;18:25. DOI: 10.1186/s12882-016-0435-z</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155. DOI: 10.1111/j.1600-6143.2009.02834.x.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bobart SA, Alexander MP, Bentall A. Recurrent Glomerulonephritis in the Kidney Allograft. Indian J Nephrol. 2020; 30(6): 359–369. DOI: 10.4103/ijn.IJN_193_19</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Allen P, Chadban S, Craig JC, Lim WH, Allen RDM, Clayton PA. et al. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney International. 2017;92:461–469. DOI: 10.1016/ j.kint.2017.03.015</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Jiang SH, Kennard AL, Walters GD. Recurrent glomerulonephritis following renal transplantation and impact on graft survival. BMC Nephrol. 2018;19:344. DOI: 10.1186/s12882-018-1135-7</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ruhi Ç, Tuğcu M, Kasapoğlu U, Boynueğri B, Gümrükçü G, Ata P. et al. The Influence of Preformed Hla Class I and II Panel Reactive Antibodies on Clinical and Pathological Outcomes of Kidney Allograft. Turkish Nephrology, Dialysis and Transplantation Journal. 2016;25:73-78. DOI:10.5262/tndt.2016.1001.08</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Schinstock C.A., Gandhi M.J., Stegall M.D. Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians. Transplantation. 2016;100(8):1619–1628. DOI: 10.1097/TP.0000000000001203</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Belyuk K.S., Mogilevets E.V., Povolanskiy YuI., Sonchik A.K., Pyshko A.Y., Barkova O.N., et al. Analysis of kidney transplantation results in patients with chronic renal disease. Transplantologiya. The Russian Journal of Transplantation. 2019;11(1):61–70. DOI: 10.23873/2074-0506-2019-11-1-61-70. Russian (Белюк К.С., Могилевец Э.В., Поволанский Ю.И., Сончик А.К., Пышко А.Я., Баркова О.Н. и др. Анализ результатов трансплантации почки у пациентов с хронической почечной недостаточностью. Трансплантология. 2019;11(1):61–70. DOI:10.23873/2074-0506-2019-11-1-61-70).</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Vatazin AV, Zulkarnaev AB, Stepanov VA. Survival analysis of patients in the waiting list for kidney transplantation in terms of competing risks. Russian Journal of Transplantology and Artificial Organs. 2019;21(1):35-45. DOI: 10.15825/1995-1191-2019-1-35-45. Russian (Ватазин АВ, Зулькарнаев АБ, Степанов ВА. Анализ выживаемости пациентов в листе ожидания трансплантации почки с позиции конкурирующих рисков. Вестник трансплантологии и искусственных органов. 2019;21(1):35-45. DOI: 10.15825/1995-1191-2019-1-35-45).</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kaliyev AA, Zhakiyev ВS, Sultangereyev EВ, Rysmakhanov MS, Elemesov AA, Almyrzauly Z, et al. Results of kidney transplantation in Aktobe region of Kazakhstan. Russian Journal of Transplantology and Artificial Organs. 2018;20(1):66-69. DOI: 10.15825/1995-1191-2018-1-66-69. Russian (Калиев А.А., Жакиев Б.C., Султангереев Е.Б., Рысмаханов М.С., Елемесов А.А., Алмурзаулы Ж. и др. Результаты трансплантации почек в Актюбинской области Казахстана. Вестник трансплантологии и искусственных органов. 2018;20(1):66-69. DOI: 10.15825/1995-1191-2018-1-66-69).</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lee HS, Kang M, Kim B, Park Y. Outcomes of kidney transplantation over a 16-year period in Korea: An analysis of the National Health Information Database. PLoS ONE. 2021;16(2): e0247449. DOI: 10.1371/journal.pone.0247449</mixed-citation></ref></ref-list></back></article>
